Inovalon this week announced AstraZeneca would utilize the company’s ONE Platform to create a value-based platform to bolster the commercialization of a new therapy for Chronic Obstructive Pulmonary Disease (COPD).
According to a press release, experts under Inovalon’s Avalere branch will leverage data and analytics through the ONE Platform to “assess unmet needs and ideal care delivery models for patients with COPD.”
“AstraZeneca is committed to evolving the current system towards payment based on the value medicines [provided] to patients, payers, and the healthcare system,” Rick Suarez, AstraZeneca’s senior vice president of market access in the U.S., said in a statement. “We are committed to furthering our work in the field of value-based agreements by designing and implementing an industry-leading value platform that articulates the benefits of our innovative therapies to all stakeholders.”
To read the full press release, click here.